Geron Corporation GERN today
acknowledged the public release by BioTime, Inc. BTX of a letter to
Geron's stockholders regarding Geron's stem cell assets. Geron's Board of
Directors has, since the announcement that Geron would be discontinuing its
stem cell research and development programs, considered a number of
alternatives with respect to such programs. Consistent with its fiduciary
duties and responsibilities, and in consultation with its financial and legal
advisors, Geron's Board of Directors will diligently review BioTime's proposal
and act in a manner that the Board believes is in the best interests of
Geron's stockholders.
Stifel Nicolaus Weisel is acting as financial advisor and Weil, Gotshal &
Manges LLP is acting as legal counsel to Geron in connection with the
divestiture of Geron's stem cell assets.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in